Xagena.net - Update in Medicine

Osimertinib, phase III ADAURA trial will be unblinded early after overwhelming efficacy in the adjuvant treatment of patients with EGFR-mutated lung cancer

The ADAURA phase III trial for Tagrisso ( Osimertinib ) in the adjuvant treatment of patients with stage IB, II and IIIA epidermal growth factor receptor-mutated ( EGFRm ) non-small cell lung cancer ( ... read article

FDA has approved clinical trial for Tocilizumab to treat hospitalized patients with severe COVID-19 pneumonia

The FDA ( U.S. Food & Drug Administration ) has approved a randomized, double-blind, placebo-controlled phase III clinical trial in collaboration with BARDA ( Biomedical Advanced Research and Deve ... read article

Venclyxto in combination with Gazyvaro for patients with previously-untreated chronic lymphocytic leukemia, approved in European Union

The European Commission ( EC ) has approved Venclyxto ( Venetoclax ) in combination with Gazyvaro ( Obinutuzumab ) for the treatment of adult patients with chronic lymphocytic leukemia ( CLL ) who wer ... read article

CheckMate -025 trial: 26% of patients treated with Nivolumab are alive at five years in previously treated advanced or metastatic renal cell carcinoma

Five-year follow-up results from the phase 3 CheckMate -025 study continue to demonstrate that treatment with Nivolumab ( Opdivo ) delivers superior overall survival ( OS ) and objective response rate ... read article

FDA has required the withdrawal of the weight-loss drug Belviq from the market: potential risk of cancer outweighs the benefits

The FDA ( U.S. Food and Drug Administration ) has requested that the manufacturer of Belviq, Belviq XR ( Lorcaserin ) voluntarily withdraw the weight-loss drug from the U.S. market because a safety c ... read article

KEYNOTE-355 trial: Pembrolizumab in combination with chemotherapy met primary endpoint of progression-free survival as first-line treatment for metastatic triple-negative breast cancer with expression of PD-L1

The pivotal phase 3 KEYNOTE-355 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy met one of its dual primary endpoints of progression-free surviva ... read article

JAVELIN Bladder 100: Bavencio is the first immunotherapy to significantly prolong overall survival in locally advanced or metastatic urothelial carcinoma in the first-line setting

Phase III JAVELIN Bladder 100 study met its primary endpoint of overall survival ( OS ) at the planned interim analysis. In this study, patients with previously untreated locally advanced or metastati ... read article

FDA: Calquence for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

The FDA ( U.S. Food and Drug Administration ) has approved Calquence ( Acalabrutinib ) for the treatment of adult patients with chronic lymphocytic leukemia ( CLL ) or small lymphocytic lymphoma ( SLL ... read article

FDA has approved Invokana, a SGLT2 inhibitor, to treat diabetes-related kidney disease

Invokana ( Canagliflozin ) has been approved by the U.S. Food and Drug Administration ( FDA ) to reduce the risk of end-stage kidney disease ( ESKD ) and cardiovascular events in patients with type 2 ... read article

IMpower131: patients with advanced squamous NSCLC and with high PD-LI expression, treated with Carboplatin + nab-Paclitaxel + Atezolizumab, have experienced a longer survival rate

Patients with stage IV squamous non-small cell lung cancer ( NSCLC ) enrolled in clinical trial to test the immunotherapy Atezolizumab ( Tecentriq ) and chemotherapy against chemotherapy alone experie ... read article

KEYNOTE-024 three-year survival update: Pembrolizumab effective as first-line therapy for advanced non-small-cell lung cancer

First line Pembrolizumab ( Keytruda ) monotherapy provides durable long-term overall survival benefit compared to chemotherapy, according to data presented at the IASLC 2019 World Conference on Lung C ... read article

Belantamab mafodotin, positive headline results from the pivotal DREAMM-2 study for multiple myeloma

Positive results from the pivotal DREAMM-2 open-label, randomised study of two doses of Belantamab mafodotin ( GSK2857916 ) were announced. The 196 patients in the trial had relapsed multiple myelo ... read article

EMA has rejected the marketing authorization of the osteoporosis drug Evenity

The European Medicines Agency ( EMA ) has recommended the refusal of the marketing authorisation for Evenity, a medicine intended for the treatment of osteoporosis. Evenity was developed as a medic ... read article

FDA approves first treatment for chronic rhinosinusitis with nasal polyps: Dupixent

The FDA ( U.S. Food and Drug Administration ) has approved Dupixent ( Dupilumab ) to treat adults with nasal polyps accompanied by chronic rhinosinusitis ( prolonged inflammation of the sinuses and na ... read article

Keytruda as monotherapy for patients with metastatic small cell lung cancer with disease progression on or after Platinum-based chemotherapy and at least one other prior line of therapy: FDA approved

The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, as monotherapy for the treatment of patients with metastatic small cell lung cancer ( SCLC ... read article